Filing Flows

Filing Flows › Companies › Skinvisible › Cash flow

Skinvisible cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow$2K in Q2 2026 · $4K over twelve months

Operating cash flow$2K
Free cash flow+$2K

Analysis

In Q2 2026, Skinvisible generated $2K of operating cash flow. That is $11K more than in Q2 2025 (−$9K).

Over the twelve months to Jun 30, 2026, operating cash flow was $4K; the cash balance rose by $4K.

Operating cash flow was $2K against net income of −$256K. The largest differences: payables +$50K, prepaid and other assets +$7K, depreciation & amortization +$5K.

Free cash flow

Skinvisible: free cash flow by quarterSkinvisible: free cash flow by quarter−$28KQ2 2024−$13KQ3 2024−$32KQ1 2025−$9KQ2 2025$1KQ3 2025$2KQ4 2025−$1KQ1 2026$2KQ2 2026
Operating cash flow less capital spending.
Skinvisible: operating cash flow against capital spendingSkinvisible: operating cash flow against capital spendingOperating cash flowCapital spending−$28K$0Q2 2024−$13K$0Q3 2024−$32K$0Q1 2025−$9K$0Q2 2025$1K−$1Q3 2025$2K$0Q4 2025−$1K$0Q1 2026$2K$0Q2 2026
Latest (Q2 2026): Operating cash flow $2K, Capital spending $0.

Capital allocation, year by year

Skinvisible: where the cash came from (up) and went (down), by fiscal yearSkinvisible: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY2021: Operating cash flow $375KFY2021: Net borrowing −$180K$375KFY2021FY2022: Operating cash flow $45K$45KFY2022FY2023: Operating cash flow −$77KFY2023FY2024: Operating cash flow −$70KFY2024: Shares issued $66KFY2024: Capital spending −$9K$66KFY2024FY2025: Operating cash flow −$38KFY2025: Net borrowing $10KFY2025: Shares issued $25KFY2025: Capital spending −$4K$35KFY2025
Over these 5 years operating cash flow totalled $234K; the largest uses were operating cash flow ($185K) and net borrowing ($180K). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$4K
Debtnone
Net cash$4K

Skinvisible funds itself: free cash flow was $4K over the last twelve months, with $4K of cash and investments and no debt on the balance sheet.

Where the cash came from and went

Skinvisible: sources (+) and uses (−) of cash, Q2 2026Skinvisible: sources (+) and uses (−) of cash, Q2 2026Operating cash flow$2KCash drawn (+) / kept (−)−$2K
Skinvisible: sources (+) and uses (−) of cash, TTM to Q2 2026Skinvisible: sources (+) and uses (−) of cash, TTM to Q2 2026Cash drawn (+) / kept (−)−$4KOperating cash flow$4KNot reconciled$1

From profit to cash

Skinvisible: net income to operating cash flow, Q2 2026Skinvisible: net income to operating cash flow, Q2 2026Net income−$256KDepreciation & amortization$5KPayables$50KPrepaid and other assets$7KOperating cash flow$2K
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026$2K———−$2K$2K
Q1 2026−$1K———$1K−$1K
Q4 2025$2K———−$2K$2K
Q3 2025$1K$1——−$1K$1K
Q2 2025−$9K———$13K−$9K
Q1 2025−$32K—$10K$25K−$3K−$32K
Q3 2024−$13K——$1K$6K−$13K
Q2 2024−$28K———$1K−$28K

Skinvisible: income statement and cash flow

Skinvisible, Q2 2026: revenue $5K (0% year over year). The chart follows the revenue to costs, profit and cash.

Skinvisible: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.